Ticagrelor Versus Clopidogrel in Ischemic Stroke
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 900 participants.
Also called NCT05553613
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 900 participants
- Sponsor
- Registry
-
NCT05553613
-
- Other papers using this trial's data
- TICA-CLOP STUDY: Ticagrelor Versus Clopidogrel in Acute Moderate and Moderate-to-Severe Ischemic Stroke, a Randomized Controlled Multi-Center Trial
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- Egypt
- Registry status
- Completed
Technical summary
Registry record NCT05553613. Randomized; double masking; primary purpose treatment. Start 2022-10-01 (actual); primary completion 2023-10-01 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Ticagrelor Versus Clopidogrel in Ischemic Stroke
- Condition
- Ischemic Stroke
- Intervention (Drug)
- Ticagrelor 90 MG Oral Tablet
- Intervention (Drug)
- Clopidogrel tablet
- Lead sponsor
- Kafrelsheikh University
Record details
- Record id
cardio:ct-nct05553613- Content hash
26e6b539f61a9dddcff6694bf4ce1f1738bcc68a33e8a8fedfb3c2d3adaf6f3c